Qaytarish

Tireoglobulin

Kod:9006

Sinonimlar
ТГпрогормон щитовидной железыпроверка функции щитовидной железыфункция щитовидной железы.TgThyroid prohormoneThyroglobulin
KabiTireoglobulin

Tahlil ma'lumotlari

Tadqiqot usuli

  • Elektrokimyoluminessent immunoanaliz (ECLIA)

Kutilayotgan natija topshirish vaqti

1–2 kun

Maxsus tayyorlik

  • For infants younger than 1 year, withhold feeds for 30–40 minutes before the blood draw.
  • Do not eat for 2–3 hours before collection; water is permitted.
  • Avoid physical exertion and emotional stress for 30 minutes before collection.
  • Do not smoke during the 30 minutes prior to collection.

Qanday foydalanish

Tireoglobulin (Tg; qalqonsimon bez progormoni substrati) tahlili differensiyalangan qalqonsimon bez karsinomasida (papillyar va follikulyar) operatsiyadan keyingi kuzatuvda davoga javobni baholash, saqlanib qolgan qalqonsimon bez to‘qimasini aniqlash va qaytalanishni aniqlash uchun qo‘llanadi. Natijalar tiroidektomiya va radioyod ablatsiyasidan keyingi uzoq muddatli boshqaruvni yo‘naltiradi. O‘lchash tireotrop gormon bostirilgan holatda (TSH-bostirilgan Tg) va, ko‘rsatmaga muvofiq, ekzogen TSH bilan stimulyatsiyadan so‘ng (TSH-stimulyatsiyalangan Tg) diagnostik sezgirlikni oshirish maqsadida amalga oshirilishi mumkin. Anti-tireoglobulin antitanachalar immunoanalizlarga xalaqit berishi mumkinligi sababli, anti-Tg antitanalarni aniqlash sinovi parallel bajariladi.

Cheklovlar

Tireoglobulin — follikulyar koloidda saqlanadigan va T4 hamda T3 hosil qiluvchi yodlanish va juftlash (coupling) reaksiyalari uchun zarur bo‘lgan 660‑kDa glikoprotein. Papillyar va follikulyar qalqonsimon bez karsinomalarida ko‘pincha tireoglobulin sintezi saqlanib qoladi, shuning uchun tiroidektomiya va radioyod ablatsiyasidan so‘ng qon zardobidagi Tg qolgan yoki qaytalangan kasallik uchun marker vazifasini bajaradi. Dastlabki baholash odatda operatsiyadan keyin 6–12 oyda, TSH bostirilgan holatda o‘tkaziladi; ayrim hollarda ekzogen TSH bilan stimulyatsiya sezgirlikni oshiradi, chunki bostirilgan holatda aniqlanmaydigan Tg bo‘lgan ba’zi bemorlarda stimulyatsiyadan so‘ng aniqlanadigan konsentratsiyalar kuzatiladi. Anti‑tireoglobulin antitanachalar bemorlarning sezilarli qismida uchraydi va analizga xalaqit berish orqali Tg ni soxta past yoki aniqlanmaydigan ko‘rsatkichlarga olib kelishi mumkin; shuning uchun anti‑Tg antitanalarini bir vaqtda o‘lchash zarur. Geterofil antitanachalar ham xalaqit berishi mumkin va sitomegalovirus infeksiyasi, toksoplazmoz hamda yuqumli mononuklyoz bilan birga uchrashi mumkin. Soxta-manfiy natijalar o‘ta kichik o‘sma yuklamasida yoki minimal miqdorda yoki strukturaviy g‘ayritabiiy tireoglobulin sekretsiya qiladigan o‘smalarda kuzatiladi. Anti‑Tg antitanachalar yo‘qligida, aniqlanmaydigan TSH‑stimulyatsiyalangan Tg kelajakdagi qaytalanish uchun yuqori salbiy bashorat qiymatiga ega. Talqin klinik ko‘rik va tasvirlash usullari bilan integratsiyalanadi, kuzatuv intervallari xavfga ko‘ra individuallashtiriladi; yuqori xavfda odatda har 6 oyda, past xavfda esa yiliga bir marta.

O'lchov birliging/mL
Referens oraliq
MinMaks
555
Ko'rsatmalarPostoperative surveillance 6–12 months after completion of total thyroidectomy, High-risk differentiated thyroid carcinoma: follow-up testing approximately every 6 months, Low-risk differentiated thyroid carcinoma: follow-up testing about once per year

Natija og'ishlarining mumkin sabablari

Pasaygan daraja

  • antithyroglobulin antibodies
  • cytomegalovirus infection
  • heterophile antibodies
  • infectious mononucleosis
  • toxoplasmosis

Namunangiz talablari

NamunangizZardob
ContainerOltin/yo'lbars qopqoqli probirka (SST, gel ajratgich)
Hajm1 mL (min 0.5 mL)
Saqlash tayyorlikSovutilgan, Muzlatilgan

References

American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009 Nov;19(11):1167-214.

Zucchelli G, Iervasi A, Ferdeghini M, Iervasi G. Serum thyroglobulin measurement in the follow-up of patients treated for differentiated thyroid cancer. Q J Nucl Med Mol Imaging. 2009 Oct;53(5):482-9.

Ringel MD. Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier. Thyroid. 2011 May;21(5):487-92.

Chernecky C. C., Berger B. J. Laboratory Tests and Diagnostic Procedures. 5th ed. Saunders Elsevier; 2008.